Search Patents
  • Dna Sequence, and Recombinant Preparation of Group 4 Major Allergens From Cereals
    Publication number: 20080108561
    Abstract: The invention relates to the preparation of DNA sequences of group 4 major allergens from cereals. The invention also includes fragments, novel combinations of partial sequences and point mutations with hypoallergenic effects. The recombinant DNA molecules and the derived polypeptides, fragments, novel combinations of partial sequences and variants can be used for therapy of pollen-allergy diseases. The proteins produced by recombination can be applied to in-vitro and in-vivo diagnosis of pollen allergies.
    Type: Application
    Filed: December 1, 2004
    Publication date: May 8, 2008
    Applicant: MERCK PATENT GMBH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Process for preparing 3-hydroxymethyl cephalosporins
    Patent number: 3985742
    Abstract: Disclosed are 7.beta.-(D-5-amino-5-carboxyvaleramido)-7-methoxy-3-cephem-4-carboxylic acids which are substituted in the three position of the "cephem" nucleus by a variety of alkyl, haloalkyl or oxygen, sulfur and nitrogen containing substituents; and the salts, esters and amide derivatives thereof. Certain of the products are obtained by fermentation and others are obtained by synthetic means. The products exhibit activity against gram-negative and gram-positive bacteria.
    Type: Grant
    Filed: February 18, 1975
    Date of Patent: October 12, 1976
    Assignee: Merck & Co., Inc.
    Inventors: Edward O. Stapley, Justo M. Mata
  • Silicous film forming composition comprising block copolymer and method for producing siliceous film using same
    Patent number: 11401384
    Abstract: According to the present invention, a siliceous film forming composition, which is capable of filling trenches having narrow widths and high aspect ratios and forming a thick film, can be provided. A siliceous film forming composition comprising: (a) a block copolymer comprising a linear and/or cyclic block A having a polysilane skeleton comprising 5 or more silicon and a block B having a polysilazane skeleton comprising 20 or more silicon, and (b) a solvent.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: August 2, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Takashi Fujiwara, Atsuhiko Sato
  • Inductive coupler for power line communications
    Patent number: 7215233
    Abstract: There is provided an inductive coupler for coupling a signal to a conductor. The inductive coupler includes (a) a magnetic core having an aperture through which the conductor is routed, (b) a winding wound around a portion of the magnetic core, where the signal is coupled between the winding and the conductor via the magnetic core, and (c) an electrically insulating, compressible material situated between the winding and the magnetic core, having a hardness of between about 10 and about 100 on a hardness type shore A durometer scale.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: May 8, 2007
    Assignee: Ambient Corporation
    Inventors: Yehuda Cern, Erik S. Merck
  • Organosilicon compounds
    Patent number: 6287650
    Abstract: R1—(A1)m—Z1—A2—(Z2—A3)n—W—SiXaYbZc  I in which R1, A1, A2, A3, Z1, R1, Z2, W, X, Y, Z, m, n, a, b and c are as defined below, can be used to produce homeotropic alignment of liquid-crystalline phases on surfaces.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: September 11, 2001
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Detlef Pauluth, Matthias Bremer, Edgar Böhm, Akio Osabe, Gerhard Herget, Wolfgang Hechler
  • Affinity chromatography matrix useful in purifying interleukin-1.beta. converting enzyme
    Patent number: 5278061
    Abstract: Affinity chromatography matrices are disclosed which are useful in purifying interleukin-1.beta. converting enzyme (ICE) from crude or partially purified cell lysate preparations. The chromatographic matrices comprise a specific ICE inhibitor of Formula I which is attached to an affinity column support by means of a bifunctional spacer.
    Type: Grant
    Filed: August 16, 1991
    Date of Patent: January 11, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Herb G. Bull, Kevin T. Chapman
  • Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
    Patent number: 5036067
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: March 14, 1990
    Date of Patent: July 30, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Yves Girard, Pierre Hamel, Daniel Delorme
  • Arylalkanoyl pyridazines
    Patent number: 6107295
    Abstract: Arylalkanoylpyridazine derivatives of the formula I ##STR1## and the physiologically acceptable salts thereof in whichR.sup.1, R.sup.2, R.sup.3, R.sup.4, Q and B have the meanings given in claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases and AIDS.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: August 22, 2000
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Jonas Rochus, Norbert Beier, Franz-Werner Kluxen, Michael Wolf
  • Benzofuran 2-carbox amides useful as inhibitors of leukoriene biosynthesis
    Patent number: 4933351
    Abstract: Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are inhibitors of leukotriene biosynthesis. These compounds inhibit the mammalian 5-lipoxygenase enzyme, thus preventing the metabolism of arachidonic acid to the leukotrienes. These compounds are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
    Type: Grant
    Filed: January 30, 1989
    Date of Patent: June 12, 1990
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Joseph G. Atkinson, Yvan Guindon, Cheuk K. Lau
  • Benzene derivatives and liquid-crystalline medium
    Patent number: 6159393
    Abstract: A liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, characterized in that it contains one or more compounds of the general formula I ##STR1## in which R, Y, A.sup.1, A.sup.2, Z.sup.1, Z.sup.2, L.sup.1 and m are as defined herein.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: December 12, 2000
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Kazuaki Tarumi, Ekkehard Bartmann, Volker Reiffenrath, Sabine Schoen, Detlef Pauluth, Brigitte Schuler, Eike Poetsch
  • Adhesion receptor antagonists
    Patent number: 5614535
    Abstract: Compounds of the formula I ##STR1## in which R.sup.1 and X have the meanings herein defined, their physiologically unobjectionable salts and/or solvates inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporosis, tumoral diseases, apoplexy, cardiac infarction, inflammations, arteriosclerosis and osteolytic disorders.
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: March 25, 1997
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Horst Juraszyk, Joachim Gante, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
  • Fullerene derivatives and related materials, methods, and devices
    Patent number: 9502658
    Abstract: The invention relates to improved fullerene derivatives, to methods for their synthesis and any educts or intermediates used in such methods, to compositions and formulations containing fullerene derivatives, to the use of the fullerene derivatives, compositions and formulations in, or for the preparation of, organic electronic (OE) devices like for example organic photovoltaic (OPV) devices or organic photodetectors (OPD), and to OE, OPV and OPD devices comprising, or being prepared from, these fullerene derivatives, compositions or formulations.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: November 22, 2016
    Assignees: NANO-C, INC., MERCK PATENT GMBH
    Inventors: Edward A. Jackson, Henning Richter, Nicolas Blouin, Stéphane Berny
  • Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
    Patent number: 7276520
    Abstract: Certain novel bicyclic N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: October 2, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Ravi P. Nargund, Zhixiong Ye, Liangqin Guo
  • D4 receptor selectivity piperazine derivatives
    Patent number: 6258813
    Abstract: Piperazine derivatives of the formula I in which R1 and R2 have the meanings given in claim 1 are dopamine ligands with a selectivity for the D4 receptor and are suitable for the treatment and prophylaxis of states of anxiety, depression, schizophrenia, obsessions, Parkinson's disease, tardive dyskinesia, nausea and disorders of the gastro-intestinal tract.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: July 10, 2001
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Michael Arlt, Henning Bottcher, Gerd Bartoszyk, Christoph Seyfried
  • Inhibitors of fatty acid binding protein (FABP)
    Patent number: 8759357
    Abstract: The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (FABP) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: June 24, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gerald W. Shipps, Jr., Clifford C. Cheng, Xioahua Huang, Abdelghani Achab, Peter Orth, Johannes H. Voigt
  • 4-Naphthyl and substituted naphthyl-3-hydroxy-3-pyrroline-2,5-diones and their use as inhibitors of glycolic acid oxidase
    Patent number: 4448786
    Abstract: Novel 4-substituted-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate kidney stone formation. A novel process for their preparation is also disclosed.
    Type: Grant
    Filed: June 25, 1982
    Date of Patent: May 15, 1984
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., Clarence S. Rooney, Haydn W. R. Williams
  • Pyrrolo-pyridazinone derivatives
    Patent number: 5426106
    Abstract: A class of 4-hydroxy-pyrrolo[1,2-b]pyridazin-2(1H)-one derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.
    Type: Grant
    Filed: March 16, 1993
    Date of Patent: June 20, 1995
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Janusz J. Kulagowski, Paul D. Leeson
  • THIAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20160185768
    Abstract: The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 4, 2014
    Publication date: June 30, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, DOUGLAS C. BESHORE, SCOTT D. KUDUK, YUNFU LUO, NA MENG, TINGTING YU
  • AUTOMATED BIOMANUFACTURING SYSTEMS, FACILITIES, AND PROCESSES
    Publication number: 20220235311
    Abstract: Disclosed are a process and an automated facility for manufacturing a purified protein of interest. The protein of interest can be a recombinant or naturally occurring protein and/or a therapeutic or other medically useful protein. For example, the disclosed process and automated facility are useful for manufacturing a purified protein drug substance.
    Type: Application
    Filed: August 8, 2021
    Publication date: July 28, 2022
    Applicants: Just-Evotec Biologics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Michael Wayne Vandiver, Eva Fan Gefroh, Rebecca Eileen McCoy, Robert James Piper, JR., Mark A. Brower, Nuno J. Dos Santos Pinto, William N. Napoli, Rachel Y. Straughn, Lisa A. Connell-Crowley, Megan J. McClure
  • 2-Aminomethyl-5-hydroxy-4H-pyran-4-one and derivatives thereof
    Patent number: 3968236
    Abstract: The 2-aminomethyl-5-hydroxy-4H-pyran-4-ones of the present invention are disclosed to have pharmaceutical utility as skeletal muscle relaxants. Also disclosed are processes for the preparation of such pyranones; pharmaceutical compositions comprising such compounds; and method of treatment comprising administering such compounds and compositions when a muscle relaxant effect is indicated.
    Type: Grant
    Filed: January 22, 1975
    Date of Patent: July 6, 1976
    Assignee: Merck & Co., Inc.
    Inventors: Joseph G. Atkinson, Joshua Rokach, Clarence S. Rooney
Narrow Results

Filter by US Classification